LaserSight Phase 2a.ORLANDO, Fla.--(BUSINESS WIRE)--Aug. 25, 1995--LaserSight (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :LASE) announced today that it has completed laser procedures on 50 percent of its Phase 2a clinical patients. The successful preliminary Phase 2a study data was presented on July 28, 1995, by Dr. Craig Beyer, National Medical Director, at the International Society for Refractive Surgery Refractive surgery A surgical procedure that corrects visual defects. Mentioned in: Photorefractive Keratectomy and Laser-Assisted In-Situ Keratomileusis refractive surgery meeting in Minneapolis. Based upon these favorable results, LaserSight will treat their remaining Phase 2a patients during September and October. LaserSight anticipates providing preliminary assessments of all Phase 2a patients at the American Academy of Ophthalmology The American Academy of Ophthalmology (AAO) is a medical association of ophthalmologists–medical doctors (MDs) specializing in eye care and surgery). The group is based in San Francisco, California. meeting in Atlanta, Georgia at the end of October. CONTACT: LaserSight Incorporated Robert Qualls, Chief Executive Officer 803/768-3505 or Gregory L. Wilson, Chief Financial Officer 314/469-3220 or Marti Benfield, Investor Relations Investor relations The process by which the corporation communicates with its investors. 314/469-3220 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion